Takeda Pharmaceutical (NYSE:TAK) Rating Lowered to “Hold” at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Other research analysts have also issued reports about the company. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings raised shares of Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, September 11th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Takeda Pharmaceutical currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Up 0.0%

NYSE TAK opened at $17.87 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock’s 50 day moving average is $18.06 and its two-hundred day moving average is $17.24. The company has a market capitalization of $57.25 billion, a price-to-earnings ratio of 52.55 and a beta of -0.07. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $19.10.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.41 by $0.54. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts forecast that Takeda Pharmaceutical will post 1.56 earnings per share for the current fiscal year.

Insider Activity at Takeda Pharmaceutical

In other news, insider Lauren Duprey sold 34,535 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.54, for a total transaction of $640,278.90. Following the completion of the sale, the insider owned 191,522 shares in the company, valued at $3,550,817.88. The trade was a 15.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Deidre Greenway sold 12,980 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total transaction of $235,067.80. Following the completion of the transaction, the insider owned 40,049 shares in the company, valued at $725,287.39. This represents a 24.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 627,457 shares of company stock worth $10,981,175 over the last 90 days. Insiders own 0.04% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SHP Wealth Management acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $42,000. Manchester Capital Management LLC raised its position in shares of Takeda Pharmaceutical by 91.4% in the 4th quarter. Manchester Capital Management LLC now owns 4,649 shares of the company’s stock valued at $72,000 after acquiring an additional 2,220 shares during the period. Harbour Investments Inc. boosted its stake in Takeda Pharmaceutical by 300.3% during the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock worth $72,000 after acquiring an additional 3,460 shares during the last quarter. Rockefeller Capital Management L.P. grew its holdings in Takeda Pharmaceutical by 30.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company’s stock valued at $81,000 after purchasing an additional 1,215 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at $163,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes prescription medicines and vaccines, with a focus on gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Iclusig and Ninlaro for certain blood cancers, and Trintellix for major depressive disorder.